Psychosomatic Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, L. S.
Right arrow Articles by Steiner, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, L. S.
Right arrow Articles by Steiner, M.
Related Collections
Right arrow Sexual Medicine: Female
Right arrow Therapeutic Interventions

Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: A Double-Blind, Placebo-Controlled Trial

Lee S. Cohen, MD, Claudio N. Soares, MD PhD, Kimberly A. Yonkers, MD, Kevin M. Bellew, MS, Ian M. Bridges, MSc and Meir Steiner, MD PhD

From the Perinatal and Reproductive Psychiatry Program (L.S.C., C.N.S.), Massachusetts General Hospital, Boston, MA; Department of Psychiatry (K.A.Y.), Yale University School of Medicine, New Haven, CT; GlaxoSmithKline Clinical Development and Medical Affairs (K.M.B.), Psychiatry, King of Prussia, PA; GlaxoSmithKline Biostatistics and Data Sciences (I.M.B.), Harlow, UK; and Women’s Health Concerns Clinic (M.S.), St. Joseph’s Hospital, Hamilton, Ontario, Canada.



View larger version (41K):

[in a new window]
  		Figure 1. Study flow.

 


View larger version (11K):

[in a new window]
  		Figure 2. VAS-total scores at baseline and at each treatment cycle for subjects randomized to receive placebo, paroxetine CR 12.5 mg, or paroxetine CR 25 mg.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Psychosomatic Society